Literature DB >> 17521324

Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes.

I Truyen1, J De Grijse, I Weets, L Kaufman, L Pipeleers, N Nanos, K Decochez, R Hilbrands, J-M Kaufman, B Keymeulen, C Mathieu, L Van Gaal, D G Pipeleers, F K Gorus.   

Abstract

Prevention trials of type I diabetes are limited by recruitment of individuals at high risk of the disease. We investigated whether demographic and biological characteristics can identify rapid progressors among first-degree relatives of known patients at intermediate (< 10%) 5-year risk. Diabetes-associated antibodies, random proinsulin : C-peptide (PI/C) ratio and HLA DQ genotype were determined (repeatedly) in 258 islet antibody-positive IA-2Antibody-negative (Abpos/IA-2Aneg) normoglycaemic first-degree relatives. During follow-up (median 81 months), 14 of 258 Abpos/IA-2Aneg relatives developed type I diabetes; 13 (93%) of them had persistent antibodies conferring a 12% [95% confidence interval (CI): 5-19%] 5-year risk of diabetes. In Abpos/IA-2Aneg relatives with persistent antibodies (n = 126), the presence of >/= 1 HLA DQ susceptibility haplotype in the absence of a protective haplotype (P = 0.033) and appearance on follow-up of a high PI/C ratio (P = 0.007) or IA-2A-positivity (P = 0.009) were identified as independent predictors of diabetes. In persistently antibody-positive relatives with HLA DQ risk a recurrently high PI/C ratio or development of IA-2A identified a subgroup (n = 32) comprising 10 of 13 (77%) prediabetic relatives and conferred a 35% (95% CI: 18-53%) 5-year risk. Under age 15 years, 5-year progression (95% CI) was 57% (30-84%) and sensitivity 62%. In the absence of IA-2A, the combination of antibody persistence, HLA DQ risk and elevated PI/C ratio or later development of IA-2A and young age defines a subgroup of relatives with a high risk of type I diabetes (>/= 35% in 5 years). Together with initially IA-2A-positive relatives these individuals qualify for standardized beta cell function tests in view of prevention trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17521324      PMCID: PMC1941942          DOI: 10.1111/j.1365-2249.2007.03416.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

Review 2.  Follow-up report on the diagnosis of diabetes mellitus.

Authors:  Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

Review 3.  CD3-specific antibody-induced active tolerance: from bench to bedside.

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

4.  IA-2 autoantibodies predict impending type I diabetes in siblings of patients.

Authors:  K Decochez; I H De Leeuw; B Keymeulen; C Mathieu; R Rottiers; I Weets; E Vandemeulebroucke; I Truyen; L Kaufman; F C Schuit; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2002-11-12       Impact factor: 10.122

5.  Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study.

Authors:  A G Ziegler; M Hummel; M Schenker; E Bonifacio
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

6.  Genetic risk determines the emergence of diabetes-associated autoantibodies in young children.

Authors:  Antti Kupila; Päivi Keskinen; Tuula Simell; Satu Erkkilä; Paula Arvilommi; Sari Korhonen; Teija Kimpimäki; Minna Sjöroos; Matti Ronkainen; Jorma Ilonen; Mikael Knip; Olli Simell
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

7.  The rare HLA-DQA1*03-DQB1*02 haplotype confers susceptibility to type 1 diabetes in whites and is preferentially associated with early clinical disease onset in male subjects.

Authors:  Jan E van Autreve; Ilse Weets; Béatrice Gulbis; Françoise Vertongen; Frans K Gorus; Bart J van der Auwera
Journal:  Hum Immunol       Date:  2004-07       Impact factor: 2.850

8.  Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics.

Authors:  Peter Achenbach; Katharina Warncke; Jürgen Reiter; Heike E Naserke; Alistair J K Williams; Polly J Bingley; Ezio Bonifacio; Anette-G Ziegler
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

9.  European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.

Authors:  E A M Gale; P J Bingley; C L Emmett; T Collier
Journal:  Lancet       Date:  2004-03-20       Impact factor: 79.321

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  2 in total

1.  An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age.

Authors:  I Vermeulen; I Weets; O Costa; M Asanghanwa; K Verhaeghen; K Decochez; J Ruige; K Casteels; J Wenzlau; J C Hutton; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2011-11-18       Impact factor: 10.122

Review 2.  Altered β-Cell Prohormone Processing and Secretion in Type 1 Diabetes.

Authors:  Teresa Rodriguez-Calvo; Yi-Chun Chen; C Bruce Verchere; Leena Haataja; Peter Arvan; Pia Leete; Sarah J Richardson; Noel G Morgan; Wei-Jun Qian; Alberto Pugliese; Mark Atkinson; Carmella Evans-Molina; Emily K Sims
Journal:  Diabetes       Date:  2021-05-04       Impact factor: 9.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.